Recent Updates
Recently added Catalysts
IBRX Positive Sentiment

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

Friday, October 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ImmunityBio has published long-term results from its Phase 2/3 QUILT-3.032 study, demonstrating that the combination of ANKTIVA® and BCG leads to an 84% cystectomy avoidance rate at three years in patients with BCG-unresponsive NMIBC. Additionally, complete responses were observed beyond 53 months, showcasing the potential of this treatment approach.

Market Sentiment Analysis

POSITIVE FACTORS

  • 84% cystectomy avoidance at three years indicates strong treatment efficacy.
  • Long-term data shows complete responses beyond 53 months.
  • Combination therapy with ANKTIVA® and BCG demonstrates promising results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
Nogapendekin alfa inbakicept
NDA/BLA · NSCLC Stage IV

Full Press Release Details

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Highl

Frequently Asked Questions

What is the main finding of the Phase 3 study?

The study found an 84% cystectomy avoidance rate at three years.

What treatment was evaluated in the study?

The study evaluated ANKTIVA® in combination with BCG.

How long were complete responses observed?

Complete responses were observed beyond 53 months.

What type of cancer was targeted in the study?

The study targeted BCG-unresponsive non-muscle invasive bladder cancer.

ShareAdd on Google
Tags: IBRX ImmunityBio non-muscle invasive bladder cancer BCG ANKTIVA
Last updated: Oct 16, 2026

Biotech snapshot

Cash runway
$357M liquidity · $22M/mo burn
~14 mo
Low dilution risk
Lead asset
Nogapendekin alfa inbakiceptNDA/BLA
NSCLC Stage IV →

Catalyst track record

+48%
best trade around IBRX's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for IBRX.

See every catalyst's timing & PoA →